Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 106, Issue 7, 2012, Pages 437-444

  Sidibe, Mariam ^a   Yactayo, Sergio ^b   Kalle, Abdoulaye ^c   Sall, Amadou A ^d   Sow, Samba ^e   Ndoutabe, Modjirom ^f   Perea, William ^b   Avokey, Fenella ^g   Lewis, Rosamund F ^b   Veit, Olivia ^b  

^a Ministry of Health   (Mali)

^b Global Alert and Response (HSE/GAR)   (Switzerland)

^c Centre Hospitalier Universitaire Gabriel Tourem   (Mali)

^d INSTITUT PASTEUR DE DAKAR   (Senegal)

^e Center for Vaccine Development   (Mali)

^f WHO   (Mali)

^g World Health Organization Ouagadougou   (Burkina Faso)

Author keywords

Adequate immune titre; HIV; Mali; Safety; Yellow fever vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS RNA; YELLOW FEVER VACCINE;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; DEATH; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH PROGRAM; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MALI; PREVENTIVE MEDICINE; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV SEROPOSITIVITY; HUMANS; IMMUNIZATION; MALE; MALI; MIDDLE AGED; NEUTRALIZATION TESTS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

FLAVIVIRUS;

EID: 84862136101     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2012.04.002     Document Type: Article

References (31)

1. Monath T.P. Yellow fever: an update. Lancet Infect Dis 2001, 1:11-20.
2. WHO. Update on progress controlling yellow fever in Africa, 2004-2008. Wkly Epidemiol Rec 2008;83:450-8.
3. Lindsey N.P., Schroeder B.A., Miller E.R., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
4. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101:967-971.
5. Domingo C., Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf 2009, 8:211-221.
6. Barrett A.D., Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol 2009, 21:308-313.
7. Khromava A.Y., Eidex R.B., Weld L.H., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
8. Cetron M.S., Marfin A.A., Julian K.G., et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002, 51:1-11. quiz CE1-4.
9. Veit O., Hatz C., Niedrig M., Furrer H. Yellow fever vaccination in HIV-infected patients. HIV Therapy 2010, 4:17-26.
10. Pacanowski J., Lacombe K., Campa P., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence following yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 2012, 59:360-367.
11. UNAIDS. Report on the global AIDS epidemic 2010. Geneva: WHO; 2010. [accessed 18 Feb 2012]. http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.
12. Gershman M, Gentes ES, Sommers T, Staples JE (yellow fever), Tan KR, Arguin PM, Steele SF (malaria). Chapter 3. Infectious diseases related to travel: yellow fever and malaria information, by country. CDC Health Information for International Travel (Yellow Book). Atlanta: Centers for Disease Control and Prevention; 2011. [accessed 18 Feb 2012]. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm.
13. WHO. Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec 2008;83:287-92.
14. WHO. Mali: 6 million vaccinated against yellow fever. Geneva: WHO; 2008. [accessed 18 Feb 2012]. http://www.who.int/features/2008/mali_vaccine/en.
15. Reinhardt B., Jaspert R., Niedrig M., Kostner C., L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998, 56:159-167.
16. WHO. Detection and investigation of serious adverse events following yellow fever vaccination. Guidance from an informal consultation of experts, 18-19 November 2008. Geneva: World Health Organization; 2010. [accessed 18 Feb 2012]. http://www.who.int/csr/resources/publications/HSE_GAR_ERI_2010_2/en/.
17. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4:553-574.
18. Veit O., Niedrig M., Chapuis-Taillard C., et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009, 48:659-666.
19. Receveur M.C., Thiebaut R., Vedy S., Malvy D., Mercie P., Bras M.L. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000, 31:E7-E8.
20. Tattevin P., Depatureaux A.G., Chapplain J.M., et al. Yellow fever vaccine is safe and effective in HIV-infected patients. Aids 2004, 18:825-827.
21. Pistone T., Verdiere C.H., Receveur M.C., Ezzedine K., Lafon M.E., Malvy D. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 2010, 8:461-466.
22. Sibailly T.S., Wiktor S.Z., Tsai T.F., et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997, 16:1177-1179.
23. WHO. Yellow fever in 1991. Wkly Epidemiol Rec 1993;68:209-15.
24. Meunier D.M., Aron N., Mazzariol M.J. The 1987 yellow fever epidemic in Mali: viral and immunological diagnosis. Trans R Soc Trop Med Hyg 1988, 82:767.
25. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
26. Overton E.T., Sungkanuparph S., Powderly W.G., Seyfried W., Groger R.K., Aberg J.A. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045-1048.
27. Overton E.T., Nurutdinova D., Sungkanuparph S., Seyfried W., Groger R.K., Powderly W.G. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007, 14:189-193.
28. Landrum M.L., Huppler Hullsiek K., et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009, 27:4731-4738.
29. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002, 85:131-134.
30. Wilson M.E., von Reyn C.F., Fineberg H.V. Infections in HIV-infected travelers: risks and prevention. Ann Intern Med 1991, 114:582-592.
31. Ho Y.L., Enohata T., Lopes M.H., De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 2008, 22:65-70.